Liposomal daunorubicincytarabine for Acute Myeloid Leukaemia (AML)

Daunorubicin and cytarabine are two chemotherapy drugs that have been used as a first treatment for acute myeloid leukaemia (AML) for a long time. Liposomal daunorubicin-cytarabine is a new ‘drug delivery system’ which combines daunorubicin and cytarabine within a tiny fat droplet called a liposome.

Please note - this is a digital download only and you will not receive a hardcopy through the post. 

Digital downloads

To access an instant download of our Liposomal daunorubicincytarabine for Acute myeloid leukaemia (AML) information booklet, please click here (opens as a PDF file). 

Each booklet takes us approximately six months to write and is supplied free of charge to patients, families and hospitals across the UK. It costs us approximately £3 to provide one booklet. Please consider adding a donation to your order if you can. .